Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

News

Rare Cancer News Logo

Tepylute for breast, ovarian cancer launched in US

May 16th 2025April 30th 2025

Read More

Oncology Nursing News Logo

Ready-to-Dilute Thiotepa Approved for Breast and Ovarian Adenocarcinomas

May 16th 2025April 30th 2025

Read More

Cure Today Logo

FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer

May 16th 2025April 30th 2025

Read More

The Pharma Letter Logo

Shorla wins FDA nod for ready-to-dilute Tepylute

May 16th 2025April 29th 2025

Read More

MPR LOGO

Tepylute, a Ready-to-Dilute Formulation of Thiotepa, Now Available

May 16th 2025April 29th 2025

Read More

FDA Approval and U.S. Launch of Tepylute® 15 MG AND 100 MG

June 23rd 2025April 29th 2025

Read More

Tepylute

FDA Approval and U.S. Launch of Tepylute® 15 MG AND 100 MG

July 17th 2025April 29th 2025

Read More

Shorla Oncology attending Asembia 2025

Shorla Oncology is attending AXS25 SUMMIT April 27 – May 1, 2025

April 23rd 2025

Read More

PCMA Meeting

Shorla Oncology is attending the PCMA Annual Meeting March 10-11 2025

July 17th 2025March 10th 2025

Read More

Older posts
Newer posts
Page1 … Page3 Page4 Page5 … Page20
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

STATE COMPLIANCE PROGRAM DECLARATIONS

Company number: 618033
©SHORLA ONCOLOGY® 2026

© 2026 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.